Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that its lead program, PALI-2108, will be featured in four presentations at United European Gastroenterology (UEG) Week 2026. The presentations include an oral presentation of Phase 1b findings in fibrostenotic Crohn’s disease and three moderated posters. The conference will take place October 17–20, 2026, in Barcelona, Spain.